Pharmaceuticals

Pharmaceuticals


X-ray powder diffraction analysis of pharmaceuticals or drugs in the form of organic solids involves the identification of the various crystallographic forms or polymorphs in which these solids can occur. While the chemical makeup of the active pharmaceutical ingredient or API is not changed from one crystallographic form to another, the substance’s physical properties often are. X-ray powder diffraction analysis may help to reveal the structure-property relationship of a particular polymorph in drug discovery, but it is mostly used as a reliable identifier for screening finished products and documenting  their ‘XRD’ signatures for patent applications and disputes.
X-ray powder diffraction analysis of crystalline organic salts deals with materials that have low symmetries, large units cells, low absorption and may be sensitive to prolonged exposure to ambient air and humidity. When probed with Cu Kα radiation, strong diffraction peaks can be expected as low as 3°2θ. The reflection geometry of standard powder diffractometers (Bragg-Brentano) requires extra care to minimize effects of preferred alignment or orientation of crystallites during sample mounting. In cases that require grinding of the salts, care is necessary to avoid phase changes resulting from excessive mechanical force applied to the polycrystalline material.

All of Camet’s XRD measurements on pharmaceuticals meet or exceed the standards set in USP Protocol <941>.

PHA_1t1
PHA_2t1
PHA_3t1
XRD Powder Diffraction analysis of Olanzapine 10 mg tablets
XRD Powder Diffraction analysis of Olanzapine Form 1
XRD Powder Diffraction analysis of Olanzapine containing Form 2
visa
american_express03
CAMET Research, Inc.
An X-Ray Diffraction (XRD) Laboratory
6409 Camino Vista #F, Goleta, CA 93117, USA
Phone: (805) 685-1665
Fax: (805) 685-9082
E-mail: camet@camet-lab.com
mstrcard
discover